Inverness Medical Innovations Announces Appointment of Chief Financial Officer

WALTHAM, Mass., July 28 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (AMEX:IMA) , a leading provider of women's health and nutritional products and developer of advanced medical device technologies, announced today that Christopher J. Lindop will become its Chief Financial Officer. He is expected to join the Company before the end of the third quarter. Mr. Lindop comes to the Company from Ernst & Young LLP, where he is currently an audit partner in the Boston Office. Prior to joining Ernst & Young, he was an audit partner in the Boston Office of Arthur Andersen, LLP from 1991 until 2002. Mr. Lindop has worked with a number of publicly held life science and technology companies in New England since moving to the area in 1984. He originally trained as a Chartered Accountant in the United Kingdom.

Ron Zwanziger, CEO of Inverness Medical said, "Mr. Lindop brings to the Company strong experience and a depth of understanding of our industry as well as the accounting systems in both the United States and Europe. We believe he will make an outstanding contribution to the Company."

For more information about Inverness Medical Innovations, please visit our website at

Inverness Medical Innovations manufactures and sells products for the women's health market, and is engaged in the business of developing, manufacturing, and marketing advanced medical device technologies. The Company is presently exploring new opportunities for its proprietary electrochemical and other technologies in a variety of consumer oriented applications including immuno-diagnostics with a focus on women's health and cardiology. The Company's women's health and nutritional products are distributed to consumers through established retail distribution networks such as Wal-Mart, Walgreens and CVS. Inverness is headquartered in Waltham, Massachusetts.

This press release contains forward-looking statements within the meaning of the federal securities laws. Actual results may differ materially due to numerous factors, including without limitation, the operational integration associated with acquisitions and any past or future acquisition transactions and other risks generally associated with such transactions, the effect of domestic and foreign healthcare regulatory efforts, the effect and cost of litigation related to our intellectual property and our products technological advancements and patents attained by competitors, demand for and the potential market acceptance of Inverness' current or future products, the intensely competitive environment in Inverness' markets which could reduce market share or limit the ability to increase market share, the efficacy and safety of products, the content and timing of submissions to and decisions by regulatory authorities both in the United States and abroad, the ability to manufacture sufficient quantities of product for development and commercialization activities, the ability to successfully develop and commercialize products, the effect of any operational and financial covenants or conversion or similar features contained within the terms of Inverness' borrowings, and the risks and uncertainties described in Inverness Medical Innovations' periodic reports filed with the Securities and Exchange Commission under the federal securities laws including its Annual Report on Form 10-K for the year-ended December 31, 2002. Inverness undertakes no obligation to update any forward-looking statements.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.